Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2016
Reporting Period: The filing announces financial results for the three and nine months ended September 30, 2016.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the text of this Form 8-K. The document serves solely to notify the SEC of the issuance of a press release containing the results.
Guidance, Outlook, and Risks
The filing text contains no management commentary, guidance, outlook, risk factors, or discussion of contingencies. It includes a standard disclaimer stating that the information in this report and its exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2016) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical trial progress or regulatory updates mentioned in the referenced press release, as this is a biopharmaceutical company.
- Confirm the company's cash runway and burn rate from the detailed financial statements in the press release.
- Check for any subsequent filings that may incorporate the results by reference, as this specific 8-K explicitly excludes such incorporation.